Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00357188 · ClinicalTrials.gov registry record · Phase 1

Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy Subjects

A Phase 1 study, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 1
Development phase
22
Enrollment target

NCT00357188: Completed Phase 1 study, sponsored by Bristol-Myers Squibb.

NCT00357188 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 22 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00357188, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 1
Development phase
22 participants
Enrollment target

Study Summary

The purpose of this study is to assess the exposure of Atazanavir 400 mg with Ritonavir 100 mg and with Efavirenz 600 mg compared to Atazanavir 300 mg with 100 mg without Efavirenz in Healthy Subjects

Interventions

  • DRUG Atazanavir Sulphate + Ritonavir
  • DRUG Atazanavir Sulphate + Ritonavir + Efavirenz

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2006-07
Est. Completion 2006-09
Phase Phase 1
Bristol-Myers Squibb

1,025 total trials

What the finished NCT00357188 record still lists

NCT00357188 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower).

The record links to 0 conditions, and to 2 interventions - of which Atazanavir Sulphate + Ritonavir is the first listed.

NCT00357188 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00357188 about?

NCT00357188 is a clinical study titled "Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy Subjects". The purpose of this study is to assess the exposure of Atazanavir 400 mg with Ritonavir 100 mg and with Efavirenz 600 mg compared to Atazanavir 300 mg with 100 mg without Efavirenz in Healthy Subjects

What is the current status of trial NCT00357188?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2006-07. Estimated completion is 2006-09.

What interventions are being tested in trial NCT00357188?

The interventions under investigation include: Atazanavir Sulphate + Ritonavir (DRUG), Atazanavir Sulphate + Ritonavir + Efavirenz (DRUG).

Who is sponsoring clinical trial NCT00357188?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00357188's enrollment target sits among peer trials

22 1601st of 2000 higher than 386 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00357188, the US trial registry maintained by the National Library of Medicine. NCT00357188 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.